

Precision Diagnostics and Therapeutics Program Laboratory Medicine- Bulletin

Official Communication. Date: 2023-10-23

Erythropoietin, homocysteine, and androstenedione assays no longer performed in-house

Audience: External and Internal Clients
Issuing Division: Division of Clinical Biochemistry, Precision Diagnostics & Therapeutics Program
Enquiry: Dr. Paul Yip, Division Head of Biochemistry and POCT (416) 480-6100 ext. 61594
paul.yip@sunnybrook.ca
Mary Rozmanc, Manager (416) 480-6100 ext. 67384
mary.rozmanc@sunnybrook.ca

The Division of Clinical Biochemistry will no longer be offering erythropoietin, homocysteine, and androstenedione testing in-house due to a change in instrumentation.

Samples will be sent for testing via In-Common Laboratories (ICL); collection requirements and turnaround time will remain the same. For additional test information including changes to methodology and reference ranges, please see the links below:

Erythropoietin (EPO), Serum (as of Sept 1 2023)

<https://iclabs.ca/test/686/>

Homocysteine, Plasma (as of Sept 1 2023)

<https://iclabs.ca/test/882/>

Androstenedione, Serum/Plasma (as of Oct 2 2023)

<https://iclabs.ca/test/221/>

If you have further questions or comments, please contact the Sunnybrook Laboratories directly.

The information in this Bulletin is current as of the date indicated above. However, it may be superseded by subsequent communications. Please check to make sure you are reviewing the most recent communicate."